Risultati di ricerca
13 mag 2024 · But it is still a pioneer in the field, and the company’s founders — MIT Institute Professor Phil Sharp, Professor David Bartel, Professor Emeritus Paul Schimmel, and former MIT postdocs Thomas Tuschl and Phillip Zamore — see Alnylam as a champion for the field more broadly.
13 mag 2024 · The company’s founders — MIT Institute Professor Phil Sharp, Professor David Bartel, Professor Emeritus Paul Schimmel, and former MIT postdocs Thomas Tuschl and Phillip Zamore — see Alnylam as a champion for the field more broadly.
8 mag 2024 · Paul Schimmel; Research 14 Apr 2023 Nature Cell Biology. Volume: 25, P: 592-603. All Research & Reviews. News and Comment. Keeping membraneless organelles apart.
10 mag 2024 · The “appearance of arbitrariness” envisaged by Francis Crick became a certainty only a few years later, with the classic experiments by Paul Schimmel and colleagues (Schimmel 1987; Schimmel et al. 1993).
- Marcello Barbieri
27 mag 2024 · Paul Schimmel First published: March 01, 2024 Alternative mRNA splicing enables the diversification of the proteome from a static genome and confers plasticity and adaptiveness on cells.
24 mag 2024 · Developer of RNA interference-based therapeutics for multiple disorders. Last updated: May 24, 2024. Who are the founders of Alnylam? Founder? Claim Profile. Alnylam has 3 founder s. They are. John Clarke, Co-Founder at Alnylam. Paul Schimmel, Co-Founder at Alnylam. Phillip Sharp, Co-Founder at Alnylam. View all Alnylam Founders.
22 mag 2024 · Paul Schimmel has an estimated net worth of $248 Million. This is based on reported shares across multiple companies, which include ALNYLAM PHARMACEUTICALS, INC., Sirtris Pharmaceuticals, Inc.,...
